[go: up one dir, main page]

NO303729B1 - 1-substituerte, 2-substituerte 1H-imidazo (4,5-c)-kinolin-4-aminer - Google Patents

1-substituerte, 2-substituerte 1H-imidazo (4,5-c)-kinolin-4-aminer

Info

Publication number
NO303729B1
NO303729B1 NO933069A NO933069A NO303729B1 NO 303729 B1 NO303729 B1 NO 303729B1 NO 933069 A NO933069 A NO 933069A NO 933069 A NO933069 A NO 933069A NO 303729 B1 NO303729 B1 NO 303729B1
Authority
NO
Norway
Prior art keywords
substituted
imidazo
amines
quinoline
hydroxyalkyl
Prior art date
Application number
NO933069A
Other languages
English (en)
Norwegian (no)
Other versions
NO933069D0 (no
NO933069L (no
Inventor
John F Gerster
Stephen L Crooks
Kyle J Lindstrom
Original Assignee
Minnesota Mining & Mfg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Minnesota Mining & Mfg filed Critical Minnesota Mining & Mfg
Publication of NO933069D0 publication Critical patent/NO933069D0/no
Publication of NO933069L publication Critical patent/NO933069L/no
Publication of NO303729B1 publication Critical patent/NO303729B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4

Landscapes

  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Emulsifying, Dispersing, Foam-Producing Or Wetting Agents (AREA)
  • Lubricants (AREA)
NO933069A 1991-03-01 1993-08-27 1-substituerte, 2-substituerte 1H-imidazo (4,5-c)-kinolin-4-aminer NO303729B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US66292691A 1991-03-01 1991-03-01
US68732691A 1991-04-18 1991-04-18
PCT/US1992/001305 WO1992015582A1 (fr) 1991-03-01 1992-02-20 1-H-IMIDAZO[4,5-c]QUINOLIN-4-AMINES SUBSTITUEES EN POSITION 1 ET SUBSTITUEES EN POSITION 2

Publications (3)

Publication Number Publication Date
NO933069D0 NO933069D0 (no) 1993-08-27
NO933069L NO933069L (no) 1993-11-01
NO303729B1 true NO303729B1 (no) 1998-08-24

Family

ID=27098631

Family Applications (1)

Application Number Title Priority Date Filing Date
NO933069A NO303729B1 (no) 1991-03-01 1993-08-27 1-substituerte, 2-substituerte 1H-imidazo (4,5-c)-kinolin-4-aminer

Country Status (18)

Country Link
EP (2) EP0872478B1 (fr)
JP (1) JP2955019B2 (fr)
AT (2) ATE229943T1 (fr)
AU (2) AU658621B2 (fr)
CA (2) CA2104782C (fr)
CZ (1) CZ285050B6 (fr)
DE (2) DE69229114T2 (fr)
DK (2) DK0582581T3 (fr)
ES (2) ES2186034T3 (fr)
HU (5) HU222111B1 (fr)
IE (1) IE920605A1 (fr)
IL (2) IL101110A (fr)
NO (1) NO303729B1 (fr)
NZ (1) NZ241784A (fr)
PH (1) PH31614A (fr)
SG (2) SG70625A1 (fr)
UA (1) UA32546C2 (fr)
WO (1) WO1992015582A1 (fr)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5266575A (en) * 1991-11-06 1993-11-30 Minnesota Mining And Manufacturing Company 2-ethyl 1H-imidazo[4,5-ciquinolin-4-amines
US5395937A (en) * 1993-01-29 1995-03-07 Minnesota Mining And Manufacturing Company Process for preparing quinoline amines
US5648516A (en) * 1994-07-20 1997-07-15 Minnesota Mining And Manufacturing Company Fused cycloalkylimidazopyridines
ES2149276T3 (es) * 1993-07-15 2000-11-01 Minnesota Mining & Mfg Imidazo(4,5-c)piridin-4-aminas.
US5352784A (en) * 1993-07-15 1994-10-04 Minnesota Mining And Manufacturing Company Fused cycloalkylimidazopyridines
US5482936A (en) * 1995-01-12 1996-01-09 Minnesota Mining And Manufacturing Company Imidazo[4,5-C]quinoline amines
US6133547A (en) * 1996-09-05 2000-10-17 Medtronic, Inc. Distributed activator for a two-dimensional shape memory alloy
US5939090A (en) 1996-12-03 1999-08-17 3M Innovative Properties Company Gel formulations for topical drug delivery
JPH10298181A (ja) * 1997-04-25 1998-11-10 Sumitomo Pharmaceut Co Ltd タイプ２ヘルパーｔ細胞選択的免疫応答抑制剤
EP1541572A1 (fr) * 2000-12-08 2005-06-15 3M Innovative Properties Company Imidazoquinoléines substituées par un thioéther
UA74852C2 (en) * 2000-12-08 2006-02-15 3M Innovative Properties Co Urea-substituted imidazoquinoline ethers
UA74593C2 (en) * 2000-12-08 2006-01-16 3M Innovative Properties Co Substituted imidazopyridines
US6664264B2 (en) * 2000-12-08 2003-12-16 3M Innovative Properties Company Thioether substituted imidazoquinolines
GB0211649D0 (en) * 2002-05-21 2002-07-03 Novartis Ag Organic compounds
WO2004009593A1 (fr) * 2002-07-23 2004-01-29 Biogal Gyogyszergyar Rt. Preparation de 1h-imidazo[4,5-c]quinoline-amines par le biais d'intermediaires de 1h-[4,5-c]quinoloine-4-phtalimide
WO2005032484A2 (fr) 2003-10-03 2005-04-14 3M Innovative Properties Company Imidazoquinolines a substitution alcoxy
NZ547467A (en) 2003-11-25 2010-06-25 3M Innovative Properties Co Substituted imidazo ring system and methods
AU2005283085B2 (en) * 2004-06-18 2012-06-21 3M Innovative Properties Company Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
US8080560B2 (en) 2004-12-17 2011-12-20 3M Innovative Properties Company Immune response modifier formulations containing oleic acid and methods
AU2006210392A1 (en) 2005-02-04 2006-08-10 Coley Pharmaceutical Group, Inc. Aqueous gel formulations containing immune response modifiers
SG164344A1 (en) 2005-02-18 2010-09-29 Novartis Vaccines & Diagnostics Srl Immunogens from uropathogenic escherichia coli
DK2351772T3 (en) 2005-02-18 2016-09-05 Glaxosmithkline Biologicals Sa Proteins and nucleic acids from meningitis / sepsis-associated Escherichia coli
US8158794B2 (en) 2005-02-23 2012-04-17 3M Innovative Properties Company Hydroxyalkyl substituted imidazoquinoline compounds and methods
AU2006216686A1 (en) 2005-02-23 2006-08-31 Coley Pharmaceutical Group, Inc. Method of preferentially inducing the biosynthesis of interferon
WO2006098852A2 (fr) * 2005-02-23 2006-09-21 Coley Pharmaceutical Group, Inc. Imidazoquinolines a substitution hydroxyalkyle
CA2602590A1 (fr) 2005-04-01 2006-10-12 Coley Pharmaceutical Group, Inc. Composes cycliques 1-pyrazolo[3,4-c] substitues comme modulateurs de la biosynthese de cytokine destines au traitement d'infections virales et de maladies neoplastiques
AU2006310337B9 (en) 2005-11-04 2013-11-28 Novartis Ag Adjuvanted influenza vaccines including cytokine-inducing agents
US8697087B2 (en) 2005-11-04 2014-04-15 Novartis Ag Influenza vaccines including combinations of particulate adjuvants and immunopotentiators
US8088790B2 (en) * 2005-11-04 2012-01-03 3M Innovative Properties Company Hydroxy and alkoxy substituted 1H-imidazoquinolines and methods
AU2006310163B2 (en) 2005-11-04 2011-09-15 Seqirus UK Limited Influenza vaccine with reduced amount of oil-in-water emulsion as adjuvant
PL1945252T3 (pl) 2005-11-04 2013-11-29 Seqirus Uk Ltd Szczepionki zawierające oczyszczone antygeny powierzchniowe otrzymane z wirusów grypy hodowanych w hodowli komórkowej i skwalen jako adiuwant
WO2007085969A2 (fr) 2006-01-27 2007-08-02 Novartis Vaccines And Diagnostics Gmbh & Co Kg Vaccins contre la grippe contenant des hémaglutinines et des protéines matricielles
CN101448523A (zh) 2006-03-24 2009-06-03 诺华疫苗和诊断有限两合公司 无需冷藏储存流感疫苗
SG173336A1 (en) 2006-03-31 2011-08-29 Novartis Ag Combined mucosal and parenteral immunization against hiv
US20100015168A1 (en) 2006-06-09 2010-01-21 Novartis Ag Immunogenic compositions for streptococcus agalactiae
GB0614460D0 (en) 2006-07-20 2006-08-30 Novartis Ag Vaccines
WO2008016475A2 (fr) 2006-07-31 2008-02-07 3M Innovative Properties Company Compositions à base de modificateurs de la réponse immunitaire et procédés
US20100166788A1 (en) 2006-08-16 2010-07-01 Novartis Vaccines And Diagnostics Immunogens from uropathogenic escherichia coli
JP5954921B2 (ja) 2006-09-11 2016-07-20 ノバルティス アーゲー 卵を使用しないインフルエンザウイルスワクチンの作製
WO2008068631A2 (fr) 2006-12-06 2008-06-12 Novartis Ag Vaccins comprenant un antigène issu de quatre souches du virus grippal
GB0700562D0 (en) 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
CA2686163A1 (fr) * 2007-05-08 2008-11-13 Astrazenca Ab Imidazoquinolines dotees de proprietes immuno-modulatrices
EA201070066A1 (ru) 2007-06-27 2010-06-30 Новартис Аг Вакцины против гриппа с низким содержанием добавок
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
HRP20150892T1 (hr) * 2008-03-03 2015-09-25 Novartis Ag Spojevi i sastavi kao modulatori tlr-aktivnosti
AU2009227674C1 (en) 2008-03-18 2015-01-29 Seqirus UK Limited Improvements in preparation of influenza virus vaccine antigens
CN101980707B (zh) * 2008-03-24 2015-05-20 4Sc股份有限公司 新的取代的咪唑并喹啉化合物
ES2733084T3 (es) 2009-03-06 2019-11-27 Glaxosmithkline Biologicals Sa Antígenos de Chlamydia
SG175092A1 (en) 2009-04-14 2011-11-28 Novartis Ag Compositions for immunising against staphylococcus aerus
WO2010125461A1 (fr) 2009-04-27 2010-11-04 Novartis Ag Vaccins avec adjuvants pour protéger du virus de la grippe
WO2011004263A2 (fr) 2009-07-07 2011-01-13 Novartis Ag Immunogènes d' escherichia coli conservés
ES2918381T3 (es) 2009-07-15 2022-07-15 Glaxosmithkline Biologicals Sa Composiciones de proteína F de VRS y métodos para producir las mismas
WO2011007257A1 (fr) 2009-07-16 2011-01-20 Novartis Ag Immunogènes d'escherichia coli détoxifiés
GB0918392D0 (en) 2009-10-20 2009-12-02 Novartis Ag Diagnostic and therapeutic methods
GB0919690D0 (en) 2009-11-10 2009-12-23 Guy S And St Thomas S Nhs Foun compositions for immunising against staphylococcus aureus
WO2011084726A1 (fr) * 2009-12-21 2011-07-14 3M Innovative Properties Company Compositions à base de a[bis [4-amino-2-(éthoxyméthyl)-1-(2-hydroxy-2-méthylpropyl)-1h-imidazo[4,5-c]quinolin-5-ium]a4-[(3-carboxylato-2-hydroxynaphtalén-1-yl)méthyl]-3-hydroxynaphtalène-2-carboxylate de [aa] et procédés correspondants
WO2011084725A1 (fr) * 2009-12-21 2011-07-14 3M Innovative Properties Company Compositions de 1-hydroxynaphtalène-2-carboxylate de 4-amino-2-(éthoxyméthyl)-1-(2-hydroxy-2-méthylpropyl)-1h-imidazo[4,5-c]quinolin-5-ium et procédés correspondants
WO2011080595A2 (fr) 2009-12-30 2011-07-07 Novartis Ag Immunogènes de polysaccharide conjugués à des protéines porteuses de e. coli
EA030813B1 (ru) 2010-05-26 2018-10-31 Селекта Байосайенсиз, Инк Способы генерации антительного иммунного ответа и увеличения местной индукции иммунных цитокинов при использовании синтетических наноносителей, соединенных с адъювантами
KR20130081659A (ko) 2010-06-01 2013-07-17 노파르티스 아게 인플루엔자 백신 항원의 농축 및 동결건조
EP2575872B1 (fr) 2010-06-01 2020-08-19 Seqirus UK Limited Concentration d'antigènes de vaccin sans lyophilisation
GB201009861D0 (en) 2010-06-11 2010-07-21 Novartis Ag OMV vaccines
CA2808965C (fr) 2010-08-20 2020-01-07 Novartis Ag Ensembles d'aiguilles solubles pour l'administration de vaccins contre la grippe
US9994443B2 (en) 2010-11-05 2018-06-12 Selecta Biosciences, Inc. Modified nicotinic compounds and related methods
LT2667892T (lt) 2011-01-26 2019-05-10 Glaxosmithkline Biologicals Sa Rsv imunizacijos režimas
AU2012255971A1 (en) 2011-05-13 2013-05-02 Novartis Ag Pre-fusion RSV F antigens
US8728486B2 (en) 2011-05-18 2014-05-20 University Of Kansas Toll-like receptor-7 and -8 modulatory 1H imidazoquinoline derived compounds
WO2013009564A1 (fr) 2011-07-08 2013-01-17 Novartis Ag Procédé de ligature de la tyrosine
MX354924B (es) 2011-11-07 2018-03-22 Novartis Ag Molecula portadora que comprende un antigeno spr0096 y un spr2021.
WO2013108272A2 (fr) 2012-01-20 2013-07-25 International Centre For Genetic Engineering And Biotechnology Vaccin antipaludique ciblant le stade sanguin
CA2885625A1 (fr) 2012-10-02 2014-04-10 Glaxosmithkline Biologicals S.A. Conjugues saccharidiques non lineaires
AU2013351182C1 (en) 2012-11-30 2018-11-08 Glaxosmithkline Biologicals Sa Pseudomonas antigens and antigen combinations
CN108250142B (zh) * 2013-02-01 2021-01-26 维尔斯达医疗公司 具有抗炎、抗真菌、抗寄生物和抗癌活性的胺化合物
EP2870974A1 (fr) 2013-11-08 2015-05-13 Novartis AG Vaccins conjugués de salmonelle
HUE047808T2 (hu) 2014-03-26 2020-05-28 Glaxosmithkline Biologicals Sa Mutáns Staphylococcus antigének
AR100137A1 (es) * 2014-04-22 2016-09-14 Hoffmann La Roche Compuestos 4-amino-imidazoquinolina
MX364223B (es) 2015-03-06 2019-04-16 Hoffmann La Roche Compuestos de dicarboxamida de benzazepinas.
KR102161364B1 (ko) * 2015-09-14 2020-09-29 화이자 인코포레이티드 LRRK2 억제제로서 이미다조[4,5-c]퀴놀린 및 이미다조[4,5-c][1,5]나프티리딘 유도체
JP6893501B2 (ja) 2015-09-17 2021-06-23 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト スルフィニルフェニル又はスルホンイミドイルフェニルベンザゼピン
JP7022702B2 (ja) 2016-05-23 2022-02-18 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 第二級アミド基を有するベンズアゼピンジカルボキサミド化合物
EP3464245B1 (fr) 2016-05-23 2020-10-14 H. Hoffnabb-La Roche Ag Composés de benzazépine dicarboxamide à fonction amide tertiaire
WO2017216054A1 (fr) 2016-06-12 2017-12-21 F. Hoffmann-La Roche Ag Composés de dihydropyrimidinyl-benzazépine carboxamide
TWI674261B (zh) * 2017-02-17 2019-10-11 美商英能腫瘤免疫股份有限公司 Nlrp3 調節劑
AU2018270266B2 (en) * 2017-05-19 2022-06-30 Superb Wisdom Limited Derivatives of resiquimod
KR20200019226A (ko) 2017-06-23 2020-02-21 버디 바이오파마슈티칼즈, 인크. 약학 조성물
CA3140708A1 (fr) 2019-06-18 2020-12-24 Helen Horton Association de vaccins contre le virus de l'hepatite b (vhb) et de derives de pyridopyrimidine

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1271477A (fr) * 1983-11-18 1990-07-10 John F. Gerster 1h-imidazo[4,5-c]quinoleine-4-amines
IL73534A (en) 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
EP0385630B1 (fr) * 1989-02-27 1996-11-27 Riker Laboratories, Inc. 4-Amino-1H-imidazo(4,5-c)quinolines comme antiviraux

Also Published As

Publication number Publication date
DE69232878T2 (de) 2003-11-20
HU9701083D0 (en) 1997-08-28
DE69229114D1 (de) 1999-06-10
NO933069D0 (no) 1993-08-27
PH31614A (en) 1999-01-12
UA32546C2 (uk) 2001-02-15
HU222250B1 (hu) 2003-05-28
CA2104782A1 (fr) 1992-09-02
HU222251B1 (hu) 2003-05-28
CZ178893A3 (en) 1995-10-18
NO933069L (no) 1993-11-01
EP0582581A1 (fr) 1994-02-16
HU9701084D0 (en) 1997-08-28
CA2104782C (fr) 2001-08-07
IE920605A1 (en) 1992-09-09
AU1566992A (en) 1992-10-06
IE990988A1 (en) 2000-12-13
CA2289219A1 (fr) 1992-09-02
AU658621B2 (en) 1995-04-27
NZ241784A (en) 1995-06-27
EP0872478A3 (fr) 1998-11-04
IL114570A0 (en) 1995-11-27
HU222247B1 (hu) 2003-05-28
EP0582581B1 (fr) 1999-05-06
ES2131070T3 (es) 1999-07-16
AU2715795A (en) 1995-09-21
HU9701089D0 (en) 1997-08-28
WO1992015582A1 (fr) 1992-09-17
DK0872478T3 (da) 2003-03-31
HU222111B1 (hu) 2003-04-28
AU673309B2 (en) 1996-10-31
JP2955019B2 (ja) 1999-10-04
HU211242A9 (en) 1995-11-28
IL101110A0 (en) 1992-11-15
SG46492A1 (en) 1998-02-20
DE69229114T2 (de) 1999-11-04
HUT67026A (en) 1995-01-30
DE69232878D1 (de) 2003-01-30
IL101110A (en) 1995-12-08
HU9302457D0 (en) 1993-11-29
DK0582581T3 (da) 1999-11-08
EP0872478B1 (fr) 2002-12-18
ATE179711T1 (de) 1999-05-15
ATE229943T1 (de) 2003-01-15
JPH06504789A (ja) 1994-06-02
EP0872478A2 (fr) 1998-10-21
CA2289219C (fr) 2003-05-20
CZ285050B6 (cs) 1999-05-12
IL114570A (en) 1996-10-31
SG70625A1 (en) 2000-02-22
ES2186034T3 (es) 2003-05-01

Similar Documents

Publication Publication Date Title
NO303729B1 (no) 1-substituerte, 2-substituerte 1H-imidazo (4,5-c)-kinolin-4-aminer
NO304946B1 (no) Xantinderivat samt dets anvendelse
PT920430E (pt) Derivados de purina e sua utilizacao como anticoagulantes
DE69529614D1 (de) Heterobizyklische derivate
FI822864A0 (fi) Karbapenem-derivat, foerfarande foer tillverkning av dessa och sammansaettningar innehaollande dessa
ATE143019T1 (de) Xanthin derivate
NZ242243A (en) 2-substituted adenine triphosphate derivatives and pharmaceutical compositions
AU6947401A (en) Phenylpyridazine derivatives and drugs containing the same
DK0918776T3 (da) Totalsyntese af antitumor acylfulvener
MY141488A (en) Hydroximic acid derivatives, processes for their preparation, and compositions comprising them
EP1431299A4 (fr) IMIDAZO(1,2-a)PYRIMIDINES ET COMPOSITIONS FONGICIDES LES CONTENANT
PH31682A (en) 4-Iminoquinolines, process for their preparation, and their use.
DE69218718D1 (de) Pharmazeutische Zusammensetzungen die Triazole Derivate enthalten zur rektalen Verabbrechung

Legal Events

Date Code Title Description
MK1K Patent expired